With CTLA-4 Antibody Deal, BioNTech Comes Face-to-Face with BMS’ Yervoy

(March 21, 2023) | By Tristan Manalac.

Monday, BioNTech inked an exclusive worldwide license and collaboration agreement with Maryland-based biopharma OncoC4 to develop and commercialize its investigational anti-CTLA-4 antibody ONC-392 for solid tumors.

The partnership represents BioNTech’s return to its oncology roots.

Though BioNTech is best known for its COVID-19 vaccine, it was founded in 2008 to develop and produce individualized cancer immunotherapies.